根据修改后的 MADIT-ICD 收益评分计算日本患者使用植入式心律转复除颤器的收益。

IF 3.2 2区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS ESC Heart Failure Pub Date : 2024-09-20 DOI:10.1002/ehf2.15081
Toshinori Chiba, Yusuke Kondo, Yuki Shiko, Masahiro Nakano, Kajiyama Takatsugu, Miyo Nakano, Ryo Ito, Masafumi Sugawara, Yutaka Yoshino, Satoko Ryuzaki, Yukiko Takanashi, Yuya Komai, Yoshio Kobayashi
{"title":"根据修改后的 MADIT-ICD 收益评分计算日本患者使用植入式心律转复除颤器的收益。","authors":"Toshinori Chiba, Yusuke Kondo, Yuki Shiko, Masahiro Nakano, Kajiyama Takatsugu, Miyo Nakano, Ryo Ito, Masafumi Sugawara, Yutaka Yoshino, Satoko Ryuzaki, Yukiko Takanashi, Yuya Komai, Yoshio Kobayashi","doi":"10.1002/ehf2.15081","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>The MADIT-ICD benefit score is used to stratify the risk of life-threatening arrhythmia and non-arrhythmic mortality. We sought to develop an implantable cardioverter defibrillator (ICD) benefit-prediction score for Japanese patients with ICDs.</p><p><strong>Methods: </strong>Patients who underwent ICD implantation as primary prophylaxis were retrospectively enrolled. Based on their MADIT-ICD benefit scores, we developed a modified MADIT-ICD benefit score adapted to the Japanese population. The primary endpoints were appropriate ICD therapy and all-cause death without appropriate ICD therapy (non-arrhythmic death). We used the Fine and Gray multivariate model and Cox proportional hazard regression to identify factors for adjusting the MADIT-ICD benefit-risk score specifically for the Japanese population. The scoring points for the original MADIT-ICD benefit score were adjusted to optimal points based on the multivariate analysis results in the population.</p><p><strong>Results: </strong>The study enrolled 167 patients [age, 61.9 ± 12.3 years; male individuals, 138 (82.6%); cardiac resynchronization therapy, 73 (43.7%); ischaemic cardiomyopathy, 53 (31.7%)]. Fourteen patients received anti-tachycardia pacing (ATP) therapy, and 23 received shock therapy as the initial appropriate ICD therapy. Non-arrhythmic deaths occurred in 37 patients. The original MADIT-ICD benefit score could not stratify non-arrhythmic mortality in the Japanese population. The patients were reclassified into three groups according to the modified MADIT-ICD benefit score. The modified MADIT-ICD benefit score could effectively stratify the incidence of appropriate ICD therapy and non-arrhythmic mortality. In the highest-benefit group, the 10 year cumulative rates of appropriate ICD therapy and non-arrhythmic mortality were 56.8% and 12.9%, respectively (P < 0.01). In the intermediate-benefit group, these rates were 20.2% and 40.2% (P = 0.01). In the lowest-benefit group, the incidence of non-arrhythmic deaths was 68.1%, and no patient received appropriate ICD therapy.</p><p><strong>Conclusions: </strong>The modified MADIT-ICD benefit score may be useful for stratifying ICD candidates in the Japanese population.</p>","PeriodicalId":11864,"journal":{"name":"ESC Heart Failure","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Benefit of implantable cardioverter defibrillator use in Japanese patients based on modified MADIT-ICD benefit score.\",\"authors\":\"Toshinori Chiba, Yusuke Kondo, Yuki Shiko, Masahiro Nakano, Kajiyama Takatsugu, Miyo Nakano, Ryo Ito, Masafumi Sugawara, Yutaka Yoshino, Satoko Ryuzaki, Yukiko Takanashi, Yuya Komai, Yoshio Kobayashi\",\"doi\":\"10.1002/ehf2.15081\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aims: </strong>The MADIT-ICD benefit score is used to stratify the risk of life-threatening arrhythmia and non-arrhythmic mortality. We sought to develop an implantable cardioverter defibrillator (ICD) benefit-prediction score for Japanese patients with ICDs.</p><p><strong>Methods: </strong>Patients who underwent ICD implantation as primary prophylaxis were retrospectively enrolled. Based on their MADIT-ICD benefit scores, we developed a modified MADIT-ICD benefit score adapted to the Japanese population. The primary endpoints were appropriate ICD therapy and all-cause death without appropriate ICD therapy (non-arrhythmic death). We used the Fine and Gray multivariate model and Cox proportional hazard regression to identify factors for adjusting the MADIT-ICD benefit-risk score specifically for the Japanese population. The scoring points for the original MADIT-ICD benefit score were adjusted to optimal points based on the multivariate analysis results in the population.</p><p><strong>Results: </strong>The study enrolled 167 patients [age, 61.9 ± 12.3 years; male individuals, 138 (82.6%); cardiac resynchronization therapy, 73 (43.7%); ischaemic cardiomyopathy, 53 (31.7%)]. Fourteen patients received anti-tachycardia pacing (ATP) therapy, and 23 received shock therapy as the initial appropriate ICD therapy. Non-arrhythmic deaths occurred in 37 patients. The original MADIT-ICD benefit score could not stratify non-arrhythmic mortality in the Japanese population. The patients were reclassified into three groups according to the modified MADIT-ICD benefit score. The modified MADIT-ICD benefit score could effectively stratify the incidence of appropriate ICD therapy and non-arrhythmic mortality. In the highest-benefit group, the 10 year cumulative rates of appropriate ICD therapy and non-arrhythmic mortality were 56.8% and 12.9%, respectively (P < 0.01). In the intermediate-benefit group, these rates were 20.2% and 40.2% (P = 0.01). In the lowest-benefit group, the incidence of non-arrhythmic deaths was 68.1%, and no patient received appropriate ICD therapy.</p><p><strong>Conclusions: </strong>The modified MADIT-ICD benefit score may be useful for stratifying ICD candidates in the Japanese population.</p>\",\"PeriodicalId\":11864,\"journal\":{\"name\":\"ESC Heart Failure\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2024-09-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ESC Heart Failure\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/ehf2.15081\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ESC Heart Failure","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ehf2.15081","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

目的:MADIT-ICD 收益评分用于对危及生命的心律失常和非心律失常死亡风险进行分层。我们试图为使用 ICD 的日本患者制定一个植入式心律转复除颤器(ICD)获益预测评分:方法:我们对接受 ICD 植入术作为主要预防措施的患者进行了回顾性登记。根据他们的 MADIT-ICD 效益评分,我们制定了适合日本人群的改良 MADIT-ICD 效益评分。主要终点是适当的 ICD 治疗和未接受适当 ICD 治疗的全因死亡(非心律失常死亡)。我们使用 Fine and Gray 多变量模型和 Cox 比例危险回归来确定调整 MADIT-ICD 收益风险评分的因素,特别是针对日本人群。根据该人群的多变量分析结果,将原始 MADIT-ICD 收益评分的得分点调整为最佳得分点:研究共纳入 167 名患者[年龄 61.9 ± 12.3 岁;男性 138 名(82.6%);心脏再同步化治疗 73 名(43.7%);缺血性心肌病 53 名(31.7%)]。14名患者接受了抗心动过速起搏(ATP)治疗,23名患者接受了电击治疗,作为 ICD 的初始适当治疗。37名患者死于非心律失常。最初的 MADIT-ICD 收益评分无法对日本人群的非心律失常死亡率进行分层。根据修改后的 MADIT-ICD 收益评分,患者被重新分为三组。修改后的 MADIT-ICD 收益评分能有效地对适当 ICD 治疗的发生率和非心律失常死亡率进行分层。在最高获益组中,10 年的适当 ICD 治疗累积率和非心律失常死亡率分别为 56.8% 和 12.9%(P修改后的 MADIT-ICD 收益评分可能有助于对日本人群中的 ICD 候选者进行分层。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Benefit of implantable cardioverter defibrillator use in Japanese patients based on modified MADIT-ICD benefit score.

Aims: The MADIT-ICD benefit score is used to stratify the risk of life-threatening arrhythmia and non-arrhythmic mortality. We sought to develop an implantable cardioverter defibrillator (ICD) benefit-prediction score for Japanese patients with ICDs.

Methods: Patients who underwent ICD implantation as primary prophylaxis were retrospectively enrolled. Based on their MADIT-ICD benefit scores, we developed a modified MADIT-ICD benefit score adapted to the Japanese population. The primary endpoints were appropriate ICD therapy and all-cause death without appropriate ICD therapy (non-arrhythmic death). We used the Fine and Gray multivariate model and Cox proportional hazard regression to identify factors for adjusting the MADIT-ICD benefit-risk score specifically for the Japanese population. The scoring points for the original MADIT-ICD benefit score were adjusted to optimal points based on the multivariate analysis results in the population.

Results: The study enrolled 167 patients [age, 61.9 ± 12.3 years; male individuals, 138 (82.6%); cardiac resynchronization therapy, 73 (43.7%); ischaemic cardiomyopathy, 53 (31.7%)]. Fourteen patients received anti-tachycardia pacing (ATP) therapy, and 23 received shock therapy as the initial appropriate ICD therapy. Non-arrhythmic deaths occurred in 37 patients. The original MADIT-ICD benefit score could not stratify non-arrhythmic mortality in the Japanese population. The patients were reclassified into three groups according to the modified MADIT-ICD benefit score. The modified MADIT-ICD benefit score could effectively stratify the incidence of appropriate ICD therapy and non-arrhythmic mortality. In the highest-benefit group, the 10 year cumulative rates of appropriate ICD therapy and non-arrhythmic mortality were 56.8% and 12.9%, respectively (P < 0.01). In the intermediate-benefit group, these rates were 20.2% and 40.2% (P = 0.01). In the lowest-benefit group, the incidence of non-arrhythmic deaths was 68.1%, and no patient received appropriate ICD therapy.

Conclusions: The modified MADIT-ICD benefit score may be useful for stratifying ICD candidates in the Japanese population.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
ESC Heart Failure
ESC Heart Failure Medicine-Cardiology and Cardiovascular Medicine
CiteScore
7.00
自引率
7.90%
发文量
461
审稿时长
12 weeks
期刊介绍: ESC Heart Failure is the open access journal of the Heart Failure Association of the European Society of Cardiology dedicated to the advancement of knowledge in the field of heart failure. The journal aims to improve the understanding, prevention, investigation and treatment of heart failure. Molecular and cellular biology, pathology, physiology, electrophysiology, pharmacology, as well as the clinical, social and population sciences all form part of the discipline that is heart failure. Accordingly, submission of manuscripts on basic, translational, clinical and population sciences is invited. Original contributions on nursing, care of the elderly, primary care, health economics and other specialist fields related to heart failure are also welcome, as are case reports that highlight interesting aspects of heart failure care and treatment.
期刊最新文献
Analysis of the usefulness and benefits of ultrafiltration in cardiorenal syndrome: A systematic review. Two causes of COVID-19-related myocardial injury-associated cardiogenic shock: Myocarditis and microvascular thrombosis. Trametinib alters contractility of paediatric Noonan syndrome-associated hypertrophic myocardial tissue slices. Effects of sodium-glucose co-transporter inhibitors on individual clinical endpoints and quality of life. Machine learning-based prediction of elevated N terminal pro brain natriuretic peptide among US general population.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1